Twist Bioscience Q3 2025: Record Revenue, Soaring Margins

Twist Biosciences Q3 FY2025 results are impressive, with a record revenue of $96.1 million, an 18% increase from last year. Gross margins surged to 53.4%, up from 43.3% a year ago, due to higher volumes and improved operations. SynBio contributed $35.2 million, a 7% year-over-year growth, excluding a one-time order. NGS shone with $55.3 million, a 27% increase, driven by diagnostic tests and new smaller accounts. Biopharma services added $5.6 million, a 10% growth, with a strong pipeline. Customer base expanded, particularly in academics, and the company remains optimistic about clinical strength in NGS and AI drug discovery. New products like adapter-free gene fragments will boost margins. Guidance for full-year revenue is $374-376 million, a 20% growth, with gross margins at 50.5-51% and adjusted EBITDA loss narrowing. The company aims to reach breakeven soon, focusing on top-line acceleration while maintaining margin discipline. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e936d49b5dc2f92a